Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity

Research output: Contribution to journal › Review › Research › peer-review

Standard

Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity. / Holst, Jens Juul.

In: Frontiers in Nutrition, Vol. 9, 964406, 2022.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Holst, JJ 2022, 'Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity', Frontiers in Nutrition, vol. 9, 964406. https://doi.org/10.3389/fnut.2022.964406

APA

Holst, J. J. (2022). Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity. Frontiers in Nutrition, 9, [964406]. https://doi.org/10.3389/fnut.2022.964406

Vancouver

Holst JJ. Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity. Frontiers in Nutrition. 2022;9. 964406. https://doi.org/10.3389/fnut.2022.964406

Author

Holst, Jens Juul. / Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity. In: Frontiers in Nutrition. 2022 ; Vol. 9.

Bibtex

@article{14d3bca5077947948a32cd5ec3b79848,
title = "Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity",
abstract = "Because of differential processing of the hormone precursor, proglucagon, numerous peptide products are released from the pancreatic alpha cells and the intestinal L-cells in which the (pro)glucagon gene is expressed. Of particular interest in relation to obesity are glucagon from the pancreas and oxyntomodulin and GLP-1 from the gut, all of which inhibit food intake, but the other products are also briefly discussed, because knowledge about these is required for selection and evaluation of the methods for measurement of the hormones. The distal intestinal L-cells also secrete the appetite-inhibiting hormone PYY. Characteristics of the secretion of the pancreatic and intestinal products are described, and causes of the hypersecretion of glucagon in obesity and type 2 diabetes are discussed. In contrast, the secretion of the products of the L-cells is generally impaired in obesity, raising questions about their role in the development of obesity. It is concluded that the impairment probably is secondary to obesity, but the lower plasma levels may contribute to the development.",
keywords = "glicentin, glucagon-like peptide-1 (GLP-1), gut hormones, oxyntomodulin, peptide YY, proglucagon",
author = "Holst, {Jens Juul}",
note = "Publisher Copyright: Copyright {\textcopyright} 2022 Holst.",
year = "2022",
doi = "10.3389/fnut.2022.964406",
language = "English",
volume = "9",
journal = "Frontiers in Nutrition",
issn = "2296-861X",
publisher = "Frontiers",

}

RIS

TY - JOUR

T1 - Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity

AU - Holst, Jens Juul

N1 - Publisher Copyright: Copyright © 2022 Holst.

PY - 2022

Y1 - 2022

N2 - Because of differential processing of the hormone precursor, proglucagon, numerous peptide products are released from the pancreatic alpha cells and the intestinal L-cells in which the (pro)glucagon gene is expressed. Of particular interest in relation to obesity are glucagon from the pancreas and oxyntomodulin and GLP-1 from the gut, all of which inhibit food intake, but the other products are also briefly discussed, because knowledge about these is required for selection and evaluation of the methods for measurement of the hormones. The distal intestinal L-cells also secrete the appetite-inhibiting hormone PYY. Characteristics of the secretion of the pancreatic and intestinal products are described, and causes of the hypersecretion of glucagon in obesity and type 2 diabetes are discussed. In contrast, the secretion of the products of the L-cells is generally impaired in obesity, raising questions about their role in the development of obesity. It is concluded that the impairment probably is secondary to obesity, but the lower plasma levels may contribute to the development.

AB - Because of differential processing of the hormone precursor, proglucagon, numerous peptide products are released from the pancreatic alpha cells and the intestinal L-cells in which the (pro)glucagon gene is expressed. Of particular interest in relation to obesity are glucagon from the pancreas and oxyntomodulin and GLP-1 from the gut, all of which inhibit food intake, but the other products are also briefly discussed, because knowledge about these is required for selection and evaluation of the methods for measurement of the hormones. The distal intestinal L-cells also secrete the appetite-inhibiting hormone PYY. Characteristics of the secretion of the pancreatic and intestinal products are described, and causes of the hypersecretion of glucagon in obesity and type 2 diabetes are discussed. In contrast, the secretion of the products of the L-cells is generally impaired in obesity, raising questions about their role in the development of obesity. It is concluded that the impairment probably is secondary to obesity, but the lower plasma levels may contribute to the development.

KW - glicentin

KW - glucagon-like peptide-1 (GLP-1)

KW - gut hormones

KW - oxyntomodulin

KW - peptide YY

KW - proglucagon

U2 - 10.3389/fnut.2022.964406

DO - 10.3389/fnut.2022.964406

M3 - Review

C2 - 35990325

AN - SCOPUS:85136520668

VL - 9

JO - Frontiers in Nutrition

JF - Frontiers in Nutrition

SN - 2296-861X

M1 - 964406

ER -

ID: 319236445